SCHEMBL25423964

SCHEMBL25423964

COc1ccc(-n2ncccc2=O)cc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
KDM4E B2RXH2 3/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
MYC P01106 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PTPN1 P18031 1/20 0.39
POLB P06746 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
USP7 Q93009 1/20 0.38
LMNA P02545 1/20 0.37
ATM Q13315 1/20 0.37
APP P05067 1/20 0.37
RAB9A P51151 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25422890 0.88 MAPT (0.41) ALDH1A1HPGDKDM4ECA12CA1
SCHEMBL31038311 0.88 CA12 (0.44) ALDH1A1KDM4ECA12CA1CA2
SCHEMBL28328775 0.77 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EPTGS1PTGS2
SCHEMBL8380196 0.75 PDE4B (0.43) HPGDKDM4ECA12CA1CA2
SCHEMBL15924317 0.75 CA12 (0.43) ALDH1A1HPGDKDM4ECA12CA1
SCHEMBL3343670 0.73 CA1 (0.47) ALDH1A1HPGDKDM4ECA12CA1
SCHEMBL30745155 0.73 MGLL (0.50) ALDH1A1HPGDKDM4ECA12CA1
SCHEMBL5323825 0.73 ALDH1A1 (0.57) ALDH1A1HPGDKDM4EPTGS1PTGS2
SCHEMBL29151112 0.73 MGLL (0.50) ALDH1A1HPGDKDM4ECA12CA1
SCHEMBL5806043 0.70 CYP11B1 (0.52) ALDH1A1KDM4EPOLBLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100960-A1 NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-03-27 US disclosed
EP-4448504-A1 NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-10-23 EP disclosed
CN-118414330-A Naphthalene and quinoline analogs as RXFP1 agonists 百时美施贵宝公司 2024-07-30 CN disclosed
WO-2023114818-A1 NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100960-A1 NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 ALDH1A1 1269/4885HPGD 316/4885KDM4E 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.